



PATENT
Attorney Docket No.: ST94037A

#20
11/12/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Serge CARILLO et al.

Appl. No.: 09/405,920

Filed: September 24, 1999

For: METHOD OF ~~CANCER~~
TREATMENT BY p53 PROTEIN
CONTROL

Art Unit: 1632

Examiner: A. Beckerleg

RECEIVED

OCT 24 2002

Commissioner for Patents
Washington DC 20231

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit copies of the references listed on the attached PTO 1449 Form for consideration and request that the U.S. Patent and Trademark Office make them of record in this application.

Applicants state the following:

☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of Applicant(s) no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

☒ In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action and/or within three months of the filing date of the application. It is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-1129.

☐ This Information Disclosure Statement is being submitted after the mailing of a final Office Action, but is believed to be prior to a Notice of Allowance. Pursuant to 37 C.F.R. § 1.97(c), payment in the amount of \$180.00 as set forth in 37 C.F.R. § 1.17(p) is enclosed. The Commissioner is hereby authorized to charge any deficiency in the fees or charge any fee required to keep this application pending to our Deposit Account No. 50-1129.

While the information and references disclosed in this Information Disclosure Statement are submitted pursuant to 37 C.F.R. § 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to is "prior art" to this invention. Applicants reserve the right to contest the "prior art" status of any information submitted or asserted against the application.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. This Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed documents and information.

Dated: October 21, 2002

Respectfully submitted,
WILEY REIN & FIELDING LLP

By:


David J. Kulik Reg. No. 36,576

WILEY REIN & FIELDING LLP
Attn: Patent Administration
1776 K Street, N.W.
Washington, D.C. 20006
Telephone: 202.719.7000
Facsimile: 202.719.7049

WRFMAIN 1182684.1